Skip to main content
. 2022 Aug 15;12:13825. doi: 10.1038/s41598-022-17338-1

Figure 4.

Figure 4

Neuroinflammation in Pla2g6−/− mice is reduced by semaglutide treatment. (A) Representative micrographs of brain regions (C = cortex, H = hippocampus, T = thalamus, Cb = cerebellum) from Iba-1 stained brain sections and (B) neuropathological quantification of Iba-1 positive microglia immunostaining in Pla2g6−/− mice treated with 0.5 µg/g semaglutide once weekly (WT n = 6, Pla2g6−/− n = 4; Pla2g6−/− Sema n = 4). Scale bar = 100 µm. (C) Representative micrographs of brain regions stained with CD68 and (D) quantification of CD68 positive microglia immunostaining in Pla2g6−/− mice treated with 0.5 µg/g semaglutide once weekly (WT n = 6, Pla2g6−/− n = 4; Pla2g6−/− Sema n = 4). Scale bar = 100 µm. (E) Representative micrographs of brain regions from GFAP stained brain sections and (F) quantification of immunoreactivity of GFAP immunostaining in Pla2g6−/− mice treated with high-dose semaglutide once weekly (WT n = 6, Pla2g6−/− n. = 4; Pla2g6−/− Sema n = 4). Scale bar = 100 µm. All data are presented as individual animals mean (SEM); ordinary one-way ANOVA adjusted using Tukey’s multiple comparisons test; p values reported in Table S7. * indicates statistically significant difference between the relevant experimental group and WT controls; # indicates statistically significant difference between Pla2g6−/− Sema mice and untreated Pla2g6−/− controls.